Research programme: p38 mitogen-activated protein kinase inhibitors - Eli LillyAlternative Names: LY-479754
Latest Information Update: 07 Oct 2013
At a glance
- Originator Eli Lilly
- Class Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2013 Discontinued - Preclinical for Cancer in USA (PO)
- 06 May 2005 Preclinical trials in Cancer in USA (PO)